81.2 F
Laguna Hills
Thursday, Jun 30, 2022
-Advertisement-
-Advertisement-
Array

Aivita Drug Trials Show Promise

- Advertisement -

Aivita Biomedical Inc. in Irvine said Phase 2 clinical trials on one of its drugs showed positive results in treating glioblastoma brain cancer.

The Irvine developmental drugmaker said a 76% survival rate at 12 and 15 months after treatment with cell immunotherapies bested a control group’s 61% rate at 12 months and 48% at 15 months.

“Treatment and monitoring of patients is ongoing [but] we are very encouraged by these interim results,” Aivita Chief Medical Officer Dr. Robert Dillman said.

The drug in testing is a novel immunotherapy that includes each patient’s own immune cells-dendritic cells infused with tumor antigens specific to the patient’s tumor.

Privately held Aivita has three clinical trials ongoing. Others are testing cell-derived immunotherapies for ovarian cancer and melanoma.

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-